Trial Profile

A prospective, randomized, controlled trial for the safety and efficacy of different dosage sugammadex for reversal of rocuronium-induced deep neuromuscular blockade in morbidly obese patients undergoing Laparoscopic Bariatric Surgery

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 02 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sugammadex (Primary) ; Palonosetron; Propofol; Remifentanil; Rocuronium bromide; Sevoflurane; Sufentanil
Indications Neuromuscular blockade
Focus Adverse reactions; Therapeutic Use

02 Feb 2021 New trial record
01 Jan 2021 Primary endpoint (The time of TOF ratio to 0.9) , has been met according to according to results published in the Journal of International Medical Research
01 Jan 2021 Results published in the Journal of International Medical Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com